Business Context and Reporting Period
Jin Medical International Ltd., a Cayman Islands company with operations headquartered in Changzhou, Jiangsu Province, China, filed this Form 6-K for December 2023. The filing reports a change in the Company’s independent registered public accounting firm.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
- The Board approved the termination of Marcum Asia CPAs LLP as the Company’s independent registered public accounting firm, effective September 23, 2023.
- The Company engaged DNTW Toronto LLP as its new independent registered public accounting firm on September 23, 2023.
- The Company stated that, during Marcum Asia’s engagement, there were no disagreements regarding accounting principles or practices, financial statement disclosure, or audit scope or procedures.
- The Company reported no reportable events during Marcum Asia’s engagement, other than material weaknesses previously disclosed in the Risk Factors section of its Form F-1 registration statement filed March 21, 2023.
- The Company stated that neither it nor anyone acting on its behalf consulted DNTW regarding the matters or reportable events specified in Form 20-F Item 16F(a)(2)(i) and (ii) before DNTW’s appointment.
Guidance, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. The material weaknesses previously disclosed in the Form F-1 remain the principal risk-related item referenced in this filing. The filing includes a December 11, 2023 letter from Marcum Asia as Exhibit 16.1 concerning the auditor change.
Important Facts for Investors to Verify
- Review Marcum Asia’s Exhibit 16.1 letter for its response to the Company’s disclosures regarding the auditor change.
- Assess the nature and remediation status of the material weaknesses disclosed in the Form F-1.
- Confirm DNTW Toronto LLP’s role as the current independent registered public accounting firm and monitor future audit reports for qualification, additional reportable events, or internal-control issues.
- Note that the filing text references February 20, 2023 for part of the Marcum Asia period and February 22, 2023 as the appointment date; investors should verify the precise engagement dates in the related filings.